Which has the lower trailing P/E, NRC or TMDX?

TMDX has the lower trailing P/E: NRC trades at 82.81 and TMDX at 22.90. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, NRC or TMDX?

Over the past five years, TMDX grew revenue faster — NRC at a -0.02% CAGR versus TMDX at 86.12%.

Does NRC or TMDX pay a bigger dividend?

NRC pays a dividend (2.87% yield), while TMDX has no payments in the available dividend history.

Is NRC or TMDX more profitable?

TMDX runs the higher net margin — NRC at 4.18% versus TMDX at 22.69%.

How have NRC and TMDX total returns compared?

Over the past 5 years, NRC delivered 4.74% and TMDX delivered 24.13% annualized total return. Past performance doesn't predict future results.

NRC Health (NRC) vs TransMedics Group, Inc. (TMDX)

A side-by-side comparison of NRC Health and TransMedics Group, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 11, 2026. Differences are shown without an overall score or investment verdict.

NRC

NRC Health

$482M

$21.38HealthcareDelayed quote: Aug 11, 2026, 4:00 PM EDT

TMDX

TransMedics Group, Inc.

$3.09B

$89.36HealthcareDelayed quote: Aug 11, 2026, 4:00 PM EDT

Total return — NRC vs TMDX

growth of $100 · dividends reinvested · last 7y

NRC -39.9% (-7.0%/yr)TMDX +295.4% (+21.7%/yr)TMDX compounded faster over this window

Log scale — wide-divergence pair

NRC TMDX

NRC vs TMDX: by the numbers

•TMDX is the larger company ($3.09B vs $482M market cap).
•TMDX trades at the lower trailing earnings multiple (22.90 vs 82.81 P/E), one valuation lens rather than an overall verdict.
•TMDX converts more revenue to profit (22.69% vs 4.18% net margin).
•TMDX grew revenue faster over the past five years (86.12% vs -0.02% CAGR).
•NRC pays a dividend (2.87% yield), while TMDX has no payments in the available dividend history.

Metrics side by side

Valuation

Metric	NRC	TMDX
P/E ratio	82.81	22.90
Forward P/E	23.75	56.94
P/S ratio	3.29	5.38
P/B ratio	70.24	6.95
EV / EBITDA	23.40	33.50
FCF yield	4.70%	2.20%

Profitability

Metric	NRC	TMDX
Gross margin	56.33%	58.69%
Operating margin	10.53%	12.21%
Net margin	4.18%	22.69%
ROE	89.43%	29.28%
ROIC	14.36%	10.94%

Dividends

Metric	NRC	TMDX
Dividend yield	2.87%	N/A
Payout ratio	115.38%	N/A

Growth (annualized)

Metric	NRC	TMDX
Revenue CAGR (5Y)	-0.02%	86.12%
EPS CAGR (5Y)	-18.88%	N/A
FCF CAGR (5Y)	-14.35%	N/A
Total return CAGR (5Y)	-15.40%	24.13%

Frequently asked

Which has the lower trailing P/E, NRC or TMDX?: TMDX has the lower trailing P/E: NRC trades at 82.81 and TMDX at 22.90. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, NRC or TMDX?: Over the past five years, TMDX grew revenue faster — NRC at a -0.02% CAGR versus TMDX at 86.12%.
Does NRC or TMDX pay a bigger dividend?: NRC pays a dividend (2.87% yield), while TMDX has no payments in the available dividend history.
Is NRC or TMDX more profitable?: TMDX runs the higher net margin — NRC at 4.18% versus TMDX at 22.69%.
How have NRC and TMDX total returns compared?: Over the past 5 years, NRC delivered 4.74% and TMDX delivered 24.13% annualized total return. Past performance doesn't predict future results.

Go deeper

Full NRC analysis Full TMDX analysis Interactive comparison tool

Dig into the metrics

NRC Health P/E ratio TransMedics P/E ratio NRC Health dividend yield NRC Health ROE TransMedics ROE NRC Health operating margin TransMedics operating margin NRC Health revenue growth TransMedics revenue growth NRC Health free cash flow TransMedics free cash flow

NRC Health & TransMedics appear in these rankings

Highest Dividend Yield Stocks Fastest Revenue Growth Stocks Highest ROE Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 11, 2026.